Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Immuron Limited ( (AU:IMC) ) is now available.
Immuron Limited announced that the Uniformed Services University released topline results from a clinical trial evaluating a third-party manufactured product containing ETEC hyperimmune bovine colostrum. The trial did not achieve statistical significance for its primary endpoint, and the product was not administered according to Travelan® directions. As a result, Immuron does not consider these results reflective of Travelan®’s performance. The company plans to propose its established three-times-daily dosing schedule at an upcoming FDA meeting. Immuron continues to collaborate with military research institutions on vaccines and is advancing discussions for testing Travelan® against other E. coli strains.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
More about Immuron Limited
Immuron Limited is an Australian-based biopharmaceutical company that operates globally. The company focuses on developing and commercializing oral immunotherapeutics for the treatment of gut-mediated diseases. Its primary product, Travelan®, is designed to prevent travelers’ diarrhea caused by enterotoxigenic E. coli (ETEC) and other pathogens.
Average Trading Volume: 709,697
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$20.05M
For an in-depth examination of IMC stock, go to TipRanks’ Overview page.